The Line · the University of Alberta Alumni Association

Episode 14: Antivirals, Vaccines and Hope With Dr. D. Lorne Tyrrell, ‘68 MD

July 2, 2020·22 min·2 clips
Dr. Lorne Tyrrell, who developed the first hepatitis B antiviral, explains the two big hopes against COVID-19.
Matt Ray opens the episode by placing The Line inside the University of Alberta alumni community and its habit of telling front-line stories. He frames this finale around the pressure of COVID-19 and the question of what virologists can do when a new disease moves fast. Dr. Lorne Tyrell is introduced as an alumnus, physician, and founding director of the Li Ka-Shing Institute of Virology. His career comes into focus through the effect of his hepatitis B research, which led to the first antiviral therapy for that virus and saved the lives of hundreds of thousands, if not millions, of patients. Matt also notes Tyrell's honors, including the Alberta Order of Excellence, the Order of Canada, and the Canadian Medical Hall of Fame. Tyrell starts with a simple point: the field is looking for two big hopes, an effective vaccine and an effective antiviral serum. He says vaccines matter, but not everyone can be vaccinated, so treatment still matters. He points to hepatitis C as an example of what can happen when antivirals are good enough to treat a chronic infection and cure it. That example supports his larger argument that antivirals deserve attention on the same level as vaccines. The conversation then turns back to hepatitis B, where his own work helped change what treatment could look like. Matt and Tyrell then move to COVID-19 therapies. One of the few antivirals to show success against COVID-19 has a U of A connection. It's a drug called remdesivir. Tyrell links that drug to University of Alberta research and to Matias Gote's work on how the virus is inhibited. He describes remdesivir as an important proof of concept, not a miracle. The trial results were statistically positive, but the benefit was modest. Tyrell treats that modesty as a starting point rather than a disappointment. He argues that more clinical trials are needed to show what the drug can really do. The episode keeps circling back to early intervention. Tyrell wants people to understand the value of changing the course of disease with antivirals before severe damage sets in. The closing segment widens the frame to show how much had changed since The Line began with Dr. Kwadwo Karimantang on March 25. Matt recalls the rise from more than 438,000 confirmed cases and almost 19,000 deaths to more than 10.1 million cases and over 500,000 deaths. That comparison gives the interview historical weight and a sobering sense of momentum. The episode ends with a clear public-health point: vaccines matter, but early antivirals matter too.

As heard by us

A measured look at how antivirals and vaccines shape the fight against COVID-19.

Dr. Lorne Tyrell's interview traces COVID-19 through a broader argument for antivirals and vaccines, moving from hepatitis B progress to the search for treatments that can change the course of disease.

Read the full review in PlayNext →

Why you'd press play

If you want the COVID-19 treatment story from a scientist who changed hepatitis B care.

Read the full recommendation in PlayNext →
Listen to the show on